Eftilagimod alfa

• CAT Number: I041526
• CAS Number: 1800476-36-1
• Purity: ≥95%

Eftilagimod alfa (Cat No.: I041526) is a soluble LAG-3 (lymphocyte activation gene-3) fusion protein that functions as an immune modulator by activating antigen-presenting cells (APCs) through MHC class II binding. Unlike LAG-3 antagonists, eftilagimod alfa enhances T cell responses and promotes anti-tumor immunity. It is being evaluated in clinical trials in combination with immune checkpoint inhibitors, such as anti-PD-1 therapies, for treating various cancers. Eftilagimod alfa represents a novel immunotherapeutic approach aimed at boosting the immune system’s ability to fight tumors.

Reference

[1]. Atkinson V, et al. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. J Immunother Cancer. 2020 Nov;8(2):e001681.
[Content Brief]